Last Update 21 Aug 26
Fair value Decreased 29%CDLX: Reverse Split And Margin Outlook Will Shape Future Repricing
Analysts have trimmed their fair value estimate for Cardlytics from $8.50 to $6.00. This reflects updated assumptions for weaker revenue growth, slightly lower profit margins, and a reduced future P/E multiple.
What’s in the News for Cardlytics
- Cardlytics issued unaudited earnings guidance for the third quarter of 2026, with expected revenue in a range of US$34.0 million to US$39.0 million. The company described this as a year over year change that declines between 27% and 17% compared with the prior year period. Source: Company guidance.
- On June 3, 2026, Cardlytics received a notice from Nasdaq stating that the company’s common stock had closed below US$1.00 per share for 30 consecutive business days, which does not meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The notice does not have an immediate effect on the current listing status. Source: Nasdaq notification.
- Cardlytics has until November 30, 2026 to regain compliance with Nasdaq’s minimum bid price rule by having its closing bid price at or above US$1.00 for at least ten consecutive business days. The company may be eligible for a further 180 day period if it meets other listing criteria and notifies Nasdaq of plans to address the issue. Source: Nasdaq listing rules and company disclosure.
- The company filed a Charter Amendment in Delaware to implement a 1 for 10 reverse stock split and to reduce authorized common shares from 100,000,000 to 10,000,000. These actions were approved at the May 20, 2026 annual meeting, become effective at 5:00 p.m. Eastern Time on June 5, 2026, and are intended to help address the bid price deficiency. Source: Company corporate filing.
- Following the reverse stock split, every 10 shares of Cardlytics common stock will convert into 1 share, with approximately 5,807,863 shares outstanding after the split compared with 58,078,634 shares on June 1, 2026. The stock is scheduled to begin trading on a split adjusted basis on the Nasdaq Global Market on June 8, 2026 under a new CUSIP, 14161W303. Source: Company corporate filing.
Valuation Changes for Cardlytics
- Fair Value Estimate has been reduced from $8.50 to $6.00, which is a material cut to the assessed worth of Cardlytics shares.
- Discount Rate remains effectively unchanged at 12.54%, indicating no shift in the required return assumption used in the valuation work.
- Revenue Growth outlook has been revised lower, with the projected annual change moving from a decline of 9.06% to a steeper decline of 12.27%.
- Net Profit Margin assumption has softened slightly, moving from 10.87% to 10.40%, which implies a modestly lower share of revenue expected to convert into profit.
- Future P/E multiple has been reduced from 5.61x to 4.49x, which points to a lower valuation ratio applied to Cardlytics expected earnings.
Key Takeaways
- Expansion into diverse partnerships and innovative platforms increases user engagement and positions the company for sustainable revenue growth and operational scale.
- Enhanced data privacy compliance and advanced analytics strengthen advertiser loyalty, create pricing power, and boost recurring, high-margin revenue streams.
- Content restrictions by a major partner, platform competition, advertiser churn, slow innovation, and reliance on debt all heighten financial and operational risks for Cardlytics.
Catalysts
About Cardlytics- Operates an advertising platform in the United States and the United Kingdom.
- Rapid expansion and diversification of partnerships-with new financial institutions and the launch of the Cardlytics Rewards platform targeting non-bank publishers-position the company to access a broader and more engaged user base, directly supporting future revenue growth and operating leverage as these partners ramp.
- Increasing adoption of personalized, data-driven marketing by top-tier brands and vertical-focused go-to-market strategies enhance advertiser stickiness and spend; this trend is reinforced by Cardlytics' improved analytics capabilities and engagement-based pricing, which should drive higher net margins and recurring billings over time.
- Growing regulatory focus on consumer privacy is making first-party, consent-based purchase data (which Cardlytics uniquely provides through its bank relationships) more valuable to advertisers, creating long-term pricing power and defensibility that can support net income growth as ad budgets shift from non-consented platforms.
- Strategic investment in AI-driven analytics, enhanced customer insights portals, and self-serve dashboards is increasing advertiser ROI and accelerating sales cycles, which is likely to boost contribution margins and operational efficiency, supporting improved overall earnings.
- The accelerating success and adoption of new offerings (e.g., Rippl and Bridg CPG), as evidenced by recent high-profile partnerships and rapid billings growth in the U.K., opens incremental high-margin revenue streams and mitigates concentration risk, setting the stage for multi-year top-line and EBITDA expansion.
Cardlytics Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Cardlytics's revenue will decrease by 12.3% annually over the next 3 years.
- Analysts are not forecasting that Cardlytics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Cardlytics's profit margin will increase from -57.7% to the average US Media industry of 10.4% in 3 years.
- If Cardlytics's profit margin were to converge on the industry average, you could expect earnings to reach $13.3 million (and earnings per share of $1.85) by about August 2029, up from -$109.6 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 4.6x on those 2029 earnings, up from -0.2x today. This future PE is lower than the current PE for the US Media industry at 21.4x.
- Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 12.54%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- The sudden and material content restrictions imposed by Cardlytics' largest financial institution (FI) partner significantly reduce available inventory and campaign reach for many brands, leading to an immediate and ongoing decrease in billings and revenue, as well as heightening risks of further partner-driven platform instability in the future (impacts: revenue, earnings).
- Pricing pressure and declining monetization efficiency (evidenced by a 15% year-over-year decline in ACPU and lower revenue-to-billings margin) reflect diminished negotiating leverage and intensifying platform competition, challenging Cardlytics' long-term ability to sustain net margins and earnings.
- Weakness and churn among mid
- and small-sized U.S. advertisers, combined with ongoing softness in key verticals like travel and restaurants, point to macroeconomic and category-specific risks that may constrain overall demand for Cardlytics' core offering and pressure top-line revenue growth.
- Strategic prioritization and slower pace of investment in analytics, AI, and new products-due to financial headwinds and the need for operational retrenchment-raise concerns over Cardlytics' ability to innovate and maintain long-term competitive differentiation, threatening future revenue diversification and earnings growth.
- Reliance on debt financing to manage near-term liquidity and repay maturing notes, at a time of contracting cash flow and reduced free cash flow, indicates elevated financial risk and may further constrain the company's ability to absorb shocks, invest in growth, or withstand prolonged downturns (impacts: cash flow, potential dilution, long-term earnings).
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $6.0 for Cardlytics based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $10.0, and the most bearish reporting a price target of just $4.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $128.3 million, earnings will come to $13.3 million, and it would be trading on a PE ratio of 4.6x, assuming you use a discount rate of 12.5%.
- Given the current share price of $4.29, the analyst price target of $6.0 is 28.5% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Cardlytics?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Comments
0 commentsDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.